Investigation Report on China Entecavir 2018-2022

Choose License

Description
The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China, among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese is estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.
Entecavir, an oral drug of oral deoxyguanosine, was developed by Bristol-Myers Squibb and approved to enter the market by FDA in Mar. 2005. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd got CFDA?s approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent. According to CRI?s market survey, the annual sales value of entecavir in China rose from CNY1126.04 million in 2013 to CNY 1995.69 million in 2017 and CAGR during this period reached up to 15.38%. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 39.82% in 2017 for sales value and 23.96% for sales volume.
Compared with the original nucleoside analogue, entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term. As is known to all, new drug?s entering into the anti-HBV drug market is bound to pose a threat to old ones, forming a new competitive landscape. Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied. Therefore, entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years. 

Topics covered
-market size of entecavir in China
-competitive landscape of entecavir in Chinese market
-price of entecavir made by different manufacturers in China
-market outlook of entecavir in China
Table of Contents
1 Related Concepts of Entecavir  
1.1 Indications for Entecavir  
1.2 Development History of Entecavir in China  
1.3 Governmental Approval for Entecavir in China  
2 Survey on Sales Status of Entecavir in China, 2013-2017  
2.1 Sales Value of Entecavir  
2.1.1 Overall Sales Value  
2.1.2 Sales Value by Region  
2.2 Sales Volume of Entecavir  
2.2.1 Overall Sales Volume  
2.2.2 Sales Volume by Region 
2.3 Sales of Entecavir by Dosage Form in China, 2013-2017 
2.3.1 Capsules  
2.3.2 Tablets 
3 Major Manufacturers of Entecavir in China, 2013-2017  
3.1 Market Share of Major Manufacturers 
3.1.1 Market Share by Sales Value  
3.1.2 Market Share by Sales Volume 
3.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.  
3.2.1 Enterprise Profile 
3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China 
3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd.  
3.3.1 Enterprise Profile  
3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China  
3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd.  
3.4.1 Enterprise Profile  
3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir in China  
3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd.  
3.5.1 Enterprise Profile  
3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir in China 
3.6 Fujian Cosunter Pharmaceutical Co., Ltd.  
3.6.1 Enterprise Profile 
3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir in China  
4 Prices of Entecavir in China, 2017-2018  
4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong)  
4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude)  
4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)  
4.4 Suzhou Dawnrays Pharmaceutical Co., Ltd. (Leiyide)  
4.5 Fujian Cosunter Pharmaceutical Co., Ltd. (Enganding)  
5 Market Outlook of Entecavir in China, 2018-2022  
5.1 Forecast on Market Size 
5.2 Forecast on Market Trend 

Selected Charts
Chart Government Approval for Entecavir Dispersible Tablets in China by Sept. 2018  
Chart Sales Volume of Entecavir in China, 2013-2017  
Chart Sales Value of Entecavir in Parts of China, 2013-2017 
Chart Sales Volume of Entecavir in China, 2013-2017 
Chart Sales Volume of Entecavir in Parts of China, 2013-2017 
Chart Sales Value of Entecavir Capsules in China, 2013-2017  
Chart Sales Volume of Entecavir Capsules in China, 2013-2017 
Chart Sales Volume of Entecavir Tablets in China, 2013-2017  
Chart Sales Volume of Entecavir Tablets in China, 2013-2017 
Chart Market Share of Top 5 Entecavir Manufacturers by Sales Value, 2013-2017  
Chart Market Share of Top 5 Entecavir Manufacturers by Sales Volume, 2013-2017  
Chart Profile of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.  
Chart Sales Value of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir, 2013-2017  
Chart Sales Volume of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir, 2013-2017
Chart Profile of Sino-American Shanghai Squibb Pharmaceuticals Ltd. 
Chart Sales Value of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir, 2013-2017
Chart Sales Volume of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir, 2013-2017  
Chart Profile of Jiangxi Qingfeng Pharmaceutical Co., Ltd.  
Chart Sales Value of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017  
Chart Sales Volume of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017 
Chart Profile of Suzhou Dawnrays Pharmaceutical Co., Ltd.  
Chart Sales Value of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017  
Chart Sales Volume of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017  
Chart Profile of Fujian Cosunter Pharmaceutical Co., Ltd.  
Chart Prices of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in Parts of China in 2017  
Chart Prices of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in Parts of China in 2017  
Chart Prices of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir (Weiliqing) in Parts of China in 2017  
Chart Prices of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir (Leiyide) in Parts of China in 2017  
Chart Prices of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir (Enganding) in Parts of China in 2017  
Chart Forecast on Size of China's Entecavir Market, 2018-2022


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by China Research and Intelligence

Investigation Report on China's Basiliximab Market, 2019-2023

Description In China, 10.80% or about 150 million people have chronic kidney disease, and over 3 million of them have end-stage renal disease, i.e. uremia. According to CRI, the incidence of chronic kidney disease in China stays at a high level in re...

Investigation Report on China's Diclofenac Market, 2019-2023

Description Rheumatoid arthritis is a common frequently-occurring disease. According to the 2018 Chinese Guideline for the Diagnosis and Treatment of Rheumatoid Arthritis, in 2018, a total of 5 million people in China had rheumatoid arthritis. As an ...

Investigation Report on China's Polyene Phosphatidylcholine Market, 2019-2023

Description According to statistics, at the end of 2018, there were about 86 million hepatitis B carriers and about 10 million hepatitis C carriers in China. In 2014, the prevalence of hepatitis B surface antigen in children under five years of age d...

Investigation Report on China's Recombinant Follitropin Beta Market, 2019-2023

Description In China, the number of infertile couples is increasing. According to Chinese media, in 2018, more than 40 million people in China were infertile, with the incidence of infertility in couples of childbearing age increasing from 3% 20 year...

Investigation Report on China's Recombinant Human Endostatin Market, 2019-2023

Description In 2008, lung cancer replaced liver cancer to be the malignant tumor with the highest fatality rate in China. Over the past 30 years, lung cancer has become a heavy burden on the Chinese people and society. In 2017, the number of lung can...

New Pharmaceuticals and Healthcare Reports